Targovax receives Fast Track designation for ONCOS-102 in melanoma
· The US FDA grants ONCOS-102 Fast Track designation for PD-1-refractory advanced melanoma · Fast Track designation further strengthens the opportunity for accelerated approval for ONCOS-102 in melanoma Oslo, Norway 22 June 2021 – Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA. The US FDA has granted Fast Track designation to ONCOS-102 based on the